289 related articles for article (PubMed ID: 15351854)
1. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
[TBL] [Abstract][Full Text] [Related]
2. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial.
Svoboda P; Barton RP; Barbarash OL; Butylin AA; Jacobs BR; Lata J; Haire WD; Jaff MR; Firszt CM; Mouginis TL; Schuerr DM; Schulz GA; Schwartz LB; El-Shahawy MA
Crit Care Med; 2004 Oct; 32(10):1990-6. PubMed ID: 15483405
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients.
Deitcher SR; Fraschini G; Himmelfarb J; Schuman E; Smith TJ; Schulz GA; Firszt CM; Mouginis TL
J Vasc Interv Radiol; 2004 Jun; 15(6):575-80. PubMed ID: 15178717
[TBL] [Abstract][Full Text] [Related]
4. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
5. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases.
Molinari AC; Haupt R; Saracco P; Di Marco M; Castagnola E; Fratino G
Support Care Cancer; 2004 Dec; 12(12):840-3. PubMed ID: 15365798
[TBL] [Abstract][Full Text] [Related]
6. Urokinase administration in pediatric patients with occluded central venous catheters.
Wachs T
J Intraven Nurs; 1990; 13(2):100-2. PubMed ID: 2313458
[TBL] [Abstract][Full Text] [Related]
7. Intraluminal instillation of urokinase and autologous plasma: a method to unblock occluded central venous ports.
Seifert G; Riess H; Seeger K; Henze G; Borgmann A
BMC Cancer; 2006 Apr; 6():103. PubMed ID: 16635269
[TBL] [Abstract][Full Text] [Related]
8. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
Deitcher SR; Fesen MR; Kiproff PM; Hill PA; Li X; McCluskey ER; Semba CP;
J Clin Oncol; 2002 Jan; 20(1):317-24. PubMed ID: 11773185
[TBL] [Abstract][Full Text] [Related]
10. High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.
Shavit L; Lifschitz M; Plaksin J; Grenader T; Slotki I
Clin Nephrol; 2010 Oct; 74(4):297-302. PubMed ID: 20875382
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
[TBL] [Abstract][Full Text] [Related]
12. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.
Gabrail N; Sandler E; Charu V; Anas N; Lim E; Blaney M; Ashby M; Gillespie BS; Begelman SM
J Vasc Interv Radiol; 2010 Dec; 21(12):1852-8. PubMed ID: 21111365
[TBL] [Abstract][Full Text] [Related]
13. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
[TBL] [Abstract][Full Text] [Related]
14. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
15. High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters.
Twardowski ZJ
Am J Kidney Dis; 1998 May; 31(5):841-7. PubMed ID: 9590195
[TBL] [Abstract][Full Text] [Related]
16. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters in haematology and oncology patients (PASSPORT 2).
Kumwenda MJ; Dougherty L; Jackson A; Hill S
J Vasc Access; 2021 Jul; 22(4):568-574. PubMed ID: 32867568
[TBL] [Abstract][Full Text] [Related]
17. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
[TBL] [Abstract][Full Text] [Related]
18. Interventions for restoring patency of occluded central venous catheter lumens.
van Miert C; Hill R; Jones L
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD007119. PubMed ID: 22513946
[TBL] [Abstract][Full Text] [Related]
19. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
20. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
Haire WD; Atkinson JB; Stephens LC; Kotulak GD
Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
